Oligometastatic disease, the curative challenge in radiation oncology

Table 1 Summary of selected series of stereotactic body radiation therapy

Ref.	No. of patients (number of lesions)	Primary site	Treated site (s)	Total dose (Gy)	Local control	Toxicity
SBRT for mixed oligometastatic sites
Milano et al[26] (2012)	121 (293)	All (mostly breast and colorectal)	Mostly liver lung, lymph nodes	Median 50 Gy in 10 fr	74% (2 yr) 65% (6 yr)	G3 in 1 patient
Greco et al[27] (2011)	103 (126)	All (mostly prostate, renal, colorectal)	Majority bone, lymph node, soft tissue	18-24 Gy in 1 fr	64% (82% if > 22 Gy) (2 yr)	G3 late < 4%
SBRT for lung oligometastases
Norihisa et al[17] (2008)	34 (43)	All (mostly lung)	Lung	48 Gy/4 fr-60 Gy/5 fr	90% (2 yr)	G2, 12%/G3, 3%
Navarria et al[16] (2014)	76 (118)	All (mostly colorectal)	Lung	60 Gy/3 fr (perpherical) < 2 cm 48 Gy/4 fr (perpherical) 60 Gy/8 fr (central)	89% (3 yr)	G1, 80%
SBRT for liver oligometastases
Rusthoven et al[11] (2009)	47 (63)	All (mostly colorectal and lung)	Liver	36-60 Gy /3 fr	92% (2 yr)	≥ G3 in 1 patient
Lee et al[12] (2009)	68	All (mostly colorectal and breast)	Liver	Median 41.8 Gy (range 27.7-60 Gy/6 fr/2w)	71% (1 yr)	G3 in 8 patients G4 in 1 patient
SBRT for spinal metastases
Wang et al[13] (2012)	149 (166)	Mixed (mostly renal, breast and NSCL)	Spine	27-30 Gy in 3 fr	72.4% (2 yr)	G3 in 6 patient
Schipani et al[14] (2012)	124 (165)	Mixed (mostly lung and prostate)	Spine	18 Gy in 1 fr	92% (1 yr)	G2-G4, 0%
SBRT for adrenal oligometastases
Casamassima et al[21] (2012)	48	Mixed (mostly NSCLC and colon)	Adrenal	36 Gy in 3 fr (most common dose)	90% (2 yr)	G2 in 1 patient (adrenal insufficiency)
SBRT for lymph-node oligometastases
Jereczek-Fossa et al[22] (2014)	69 (94)	Mixed (mostly urological, gastrointestinal and gynecologic)	Single abdominal lymph node recurrence	Median 24 Gy in 3 fr	64.3% (3 yr)	G3 acute in 2 patients G4 late in 1 patient

SBRT: Stereotactic body radiation therapy; NSCLC: Non-small cell lung cancer.